The estimated Net Worth of David Hirsch is at least $18.7 Milion dollars as of 14 July 2020. David Hirsch owns over 250,000 units of Tricida Inc stock worth over $298,567 and over the last 9 years he sold TCDA stock worth over $18,080,785. In addition, he makes $283,500 as Independent Director at Tricida Inc.
Sign up
David Hirsch TCDA stock SEC Form 4 insiders trading
David has made over 8 trades of the Tricida Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 250,000 units of TCDA stock worth $4,000,000 on 14 July 2020.
The largest trade he's ever made was selling 1,000,000 units of Tricida Inc stock on 8 December 2017 worth over $17,340,000. On average, David trades about 104,667 units every 68 days since 2015. As of 14 July 2020 he still owns at least 2,714,245 units of Tricida Inc stock.
You can see the complete history of David Hirsch stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
David Hirsch biography
Dr. David Hirsch M.D., Ph.D. serves as Independent Director of the Company. Dr. Hirsch has served as a Founder and Managing Director at Longitude Capital Management, an affiliate of one of our principal stockholders, where he focuses on investments in biotechnology. From 2005 to 2006, Dr. Hirsch was Vice President of Pequot Ventures where he worked in the life sciences practice. Prior to Pequot Ventures, Dr. Hirsch was an Engagement Manager in the pharmaceutical practice of McKinsey & Co. Dr. Hirsch currently serves on the boards of directors of the following public companies: Collegium Pharmaceutical, Inc., since 2012, and Molecular Templates, Inc., since 2017. Dr. Hirsch also serves on the boards of directors of the following private companies: Inflazome, Ltd., Poseida Therapeutics, Inc., Rapid Micro Biosystems, Inc., and Velicept Therapeutics, Inc., and Amunix Pharmaceuticals, Inc., and Dr. Hirsch previously served on the boards of directors of Civitas Therapeutics, Inc., Precision Therapeutics, Inc., and Zavante Therapeutics, Inc. Dr. Hirsch received his B.A. in Biology from The Johns Hopkins University, his M.D. from Harvard Medical School and his Ph.D. in Biology from the Massachusetts Institute of Technology.
What is the salary of David Hirsch?
As the Independent Director of Tricida Inc, the total compensation of David Hirsch at Tricida Inc is $283,500. There are 12 executives at Tricida Inc getting paid more, with Gerrit Klaerner having the highest compensation of $10,168,700.
How old is David Hirsch?
David Hirsch is 49, he's been the Independent Director of Tricida Inc since 2016. There are 12 older and 3 younger executives at Tricida Inc. The oldest executive at Tricida Inc is Robert Alpern, 69, who is the Independent Director.
What's David Hirsch's mailing address?
David's mailing address filed with the SEC is C/O LONGITUDE CAPITAL PARTNERS III, LLC, 2740 SAND HILL ROAD, SECOND FLOOR, MENLO PARK, CA, 94025.
Insiders trading at Tricida Inc
Over the last 6 years, insiders at Tricida Inc have traded over $198,373,537 worth of Tricida Inc stock and bought 7,174,449 units worth $105,536,837 . The most active insiders traders include David P Bonita, Advisors Llc Orbi Med Capit... oraz Healthcare Capital Partners.... On average, Tricida Inc executives and independent directors trade stock every 8 days with the average trade being worth of $22,553. The most recent stock trade was executed by Robert J Alpern on 23 November 2022, trading 131,879 units of TCDA stock currently worth $27,695.
What does Tricida Inc's logo look like?
Complete history of David Hirsch stock trades at Collegium Pharmaceutical Inc, Molecular Templates Inc, Tricida Inc oraz Poseida Therapeutics
Tricida Inc executives and stock owners
Tricida Inc executives and other stock owners filed with the SEC include:
-
Gerrit Klaerner,
President, Chief Executive Officer, Director -
Dawn Parsell,
Executive Vice President - Clinical Development -
Geoffrey Parker,
Chief Financial Officer, Executive Vice President -
Edward Hejlek,
Senior Vice President -
Dr. Gerrit Klaerner Ph.D.,
Founder, Pres, CEO & Exec. Director -
Dr. Dawn Parsell Ph.D.,
Exec. VP of Clinical Devel. -
Geoffrey M. Parker,
COO, CFO & Exec. VP -
Robert L. McKague J.D.,
Exec. VP, Company Sec., Gen. Counsel & Chief Compliance Officer -
Dr. Wilhelm Stahl,
Exec. VP & CTO -
Klaus Veitinger,
Independent Chairman of the Board -
David Bonita,
Independent Director -
Kathryn Falberg,
Independent Director -
David Hirsch,
Independent Director -
Sandra Coufal,
Independent Director -
Robert Alpern,
Independent Director -
Marc Cobo,
Senior Vice President - Finance, Chief Accounting Officer -
Robert McKague,
Executive Vice President, General Counsel, Secretary -
Edward J. Hejlek Esq., J.D.,
Exec. VP of Intellectual Property -
Jackie Cossmon,
VP of Investor Relations & Communications -
Annie Yoshiyama,
VP of Fin. & Chief Accounting Officer -
Claire Lockey,
Chief Dev. Officer and Sr. VP -
Brian M.Sibling Capital Fun...,
-
Brian M.Sibling Capital Fun...,
-
Brian M.Sibling Capital Ven...,
-
Beek Jeroen B Van,
Chief Comm Officer and Sr VP -
Steffen Pietzke,
VP Fin & Chief Acct Officer -
Capital Partners Ii, Llc Lo...,
-
Advisors Llc Orbi Med Capit...,
-
Harbor Master Investors (Ca...,
10% owner -
Wilhelm Stahl,
EVP, Chief Tech Officer -
Brian M.Sibling Capital Ven...,
-
Susannah Cantrell,
EVP, Chief Comm. Officer -
Brian M.Sibling Capital Fun...,
-
Brian M.Sibling Capital Fun...,
-
Annie Yoshiyama,
Senior VP, Finance and CAO -
Healthcare Capital Partners...,